News & Updates

A population-based study of 146,430 Hong Kong patients with diabetes mellitus (DM) reports that optimal vs suboptimal glycaemic control is associated with reduced risk of developing hepatocellular carcinoma (HCC) and liver-related mortality.

For patients with breast cancer undergoing adjuvant radiotherapy, statin therapy appears to confer cardioprotective effects, mitigating the risk of major adverse cardiovascular event, according to a retrospective study.

A short-course induction chemotherapy conducted prior to chemoradiotherapy appears to deliver significant survival boost in locally advanced cervical cancer, according to the phase III GCIG INTERLACE trial.

The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.

A phase II trial demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in Chinese patients with advanced pancreatic cancer (APC) who received first-line treatment with nab-paclitaxel plus S-1 (AS) vs nab-paclitaxel plus gemcitabine (AG).

A secondary post hoc analysis of the phase III SPARTAN trial shows that patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who received prior prostate-directed local therapy (LT) had longer metastasis-free survival (MFS) when treated with apalutamide vs those without prior LT.